Pathway comparisons.
Compare biological targets without turning separate clinical studies into a misleading leaderboard. These guides distinguish metabolic receptor families and growth-hormone-axis mechanisms, then show which differences in study design matter to the interpretation.
Guides in this topic
Peptide FundamentalsAmycretin (Zenagamtide): What the New Trials Actually Show
Amycretin, now also reported as zenagamtide, is an engineered molecule with GLP-1 and amylin receptor activity.
Updated 2026-10-29 ↗
Research PracticeCagriSema vs Semaglutide: How to Read Combination Evidence
CagriSema research tests coadministered cagrilintide and semaglutide, not a new name for semaglutide alone.
Updated 2026-10-29 ↗
Research PracticeCotadutide: Glucose, Weight and Liver Findings Explained
Cotadutide research combines a GLP-1/glucagon receptor design with clinical measurements of glucose, weight and hepatic markers.
Updated 2026-10-29 ↗
Research PracticeEcnoglutide: What cAMP-Biased GLP-1 Signaling Means
Ecnoglutide is described as a cAMP-biased GLP-1 receptor agonist. That is a statement about signaling in an assay, not a clinical verdict that the molecule works better than all other GLP-1 medicines.
Updated 2026-10-29 ↗
Research PracticeEloralintide: Selective Amylin Design and the 48-Week Trial
Eloralintide research links a molecular design question with a human weight-management question.
Updated 2026-10-29 ↗
Research PracticeMariTide: Why a Peptide–Antibody Conjugate Is a Different Design
MariTide, or maridebart cafraglutide, combines a peptide component with an antibody-based design. That architecture helps explain why it belongs in a discussion of metabolic peptides while differing from a standalone peptide analogue.
Updated 2026-10-29 ↗
Peptide FundamentalsOrforglipron: Why a GLP-1 Drug Does Not Have to Be a Peptide
Orforglipron activates the GLP-1 receptor, but it is a small molecule rather than a peptide. That distinction is useful because online discussions often use GLP-1, injectable and peptide as if they were the same classification.
Updated 2026-10-29 ↗
Research PracticePemvidutide and MASH: Liver Endpoints Beyond Weight Loss
Pemvidutide’s IMPACT report separates two liver-biopsy questions: MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH.
Updated 2026-10-29 ↗
Research PracticePetrelintide: Reading the New Amylin Research
Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.
Updated 2026-10-29 ↗
Research PracticeRetatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons
Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.
Updated 2026-10-29 ↗
Research PracticeSemaglutide vs Tirzepatide: What Head-to-Head Evidence Shows
SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.
Updated 2026-10-29 ↗
Research PracticeVK2735: Reading VENTURE and the Oral Research Separately
VK2735 has been studied as an injected and an oral GIP/GLP-1 receptor agonist, but the two research records should not be fused into one result.
Updated 2026-10-29 ↗